Santen Pharmaceutical says eye allergy drug meets primary endpoints in Phase III trials
Santen Pharmaceutical said late stage trials for its drug to treat an allergic eye condition in children met its primary endpoint.
The company said Phase III trial for its trial drug for the condition known as vernal keratoconjunctivitis (VKC) showed efficacy and tolerability in patients aged 4–18 years.
Shigeo Taniuchi, Head of Santen Europe, said: “With these very encouraging results from Vektis, Vekacia is delivering on its promise to provide an innovative and effective treatment that significantly improves outcomes for children with severe VKC.”
VKC is a severe and recurrent allergic eye condition that mainly affects children (predominantly boys) and young adults, and which results in intense itching photophobia, painful eyes, and potentially even permanent loss of vision.
The condition is characterised by severe inflammation of the ocular surface, including the conjunctivae and cornea (keratitis).
Biogen has announced that its investigational gene therapy study for the potential treatment of choroideremia …
Celltrion has announced positive top-line data for its experimental antibody COVID-19 treatment, with Phase III …